Wuhan Hiteck Biological Pharma Co.,Ltd

XSEC:300683 Stock Report

Market Cap: CN¥3.0b

Wuhan Hiteck Biological PharmaLtd Past Earnings Performance

Past criteria checks 0/6

Wuhan Hiteck Biological PharmaLtd's earnings have been declining at an average annual rate of -69.7%, while the Biotechs industry saw earnings growing at 5.4% annually. Revenues have been growing at an average rate of 2% per year.

Key information

-69.7%

Earnings growth rate

-68.5%

EPS growth rate

Biotechs Industry Growth11.3%
Revenue growth rate2.0%
Return on equity-5.8%
Net Margin-22.8%
Last Earnings Update31 Mar 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Wuhan Hiteck Biological PharmaLtd makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

XSEC:300683 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Mar 24596-136261133
31 Dec 23602-121238129
30 Sep 23580-59242127
30 Jun 23588-44238115
31 Mar 23661-23235116
01 Jan 23689-14236121
30 Sep 2276928237116
30 Jun 2277639253118
31 Mar 2262321251113
01 Jan 2261528256103
30 Sep 215684245105
30 Jun 21557-1427394
31 Mar 21617-1527095
31 Dec 20524-2525586
30 Sep 20498-1627475
30 Jun 20494328571
31 Mar 205293733962
01 Jan 206206338263
30 Sep 196498642353
30 Jun 1964110341548
31 Mar 1961510038841
31 Dec 185919439830
30 Sep 1858511039126
30 Jun 1863011940533
31 Mar 1871213549124
31 Dec 1775014251924
30 Sep 1782616858017
30 Jun 178271656010
31 Mar 177911616860
31 Dec 167711575590
31 Dec 15679834790
31 Dec 145491104010
31 Dec 13356782450

Quality Earnings: 300683 is currently unprofitable.

Growing Profit Margin: 300683 is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 300683 is unprofitable, and losses have increased over the past 5 years at a rate of 69.7% per year.

Accelerating Growth: Unable to compare 300683's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 300683 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-3.2%).


Return on Equity

High ROE: 300683 has a negative Return on Equity (-5.81%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.